| | Characteristic | Levels | Overall |
| | n | | 374 | | T stage, n (%) | T1 | 183 (49.3%) | | T2 | 95 (25.6%) | | T3 | 80 (21.6%) | | T4 | 13 (3.5%) |
| | N stage, n (%) | N0 | 254 (98.4%) | | N1 | 4 (1.6%) |
| | M stage, n (%) | M0 | 268 (98.5%) | | M1 | 4 (1.5%) |
| | Pathologic stage, n (%) | Stage I | 173 (49.4%) | | Stage II | 87 (24.9%) | | Stage III | 85 (24.3%) | | Stage IV | 5 (1.4%) |
| | Tumor status, n (%) | Tumor free | 202 (56.9%) | | With tumor | 153 (43.1%) |
| | Gender, n (%) | Female | 121 (32.4%) | | Male | 253 (67.6%) |
| | Race, n (%) | Asian | 160 (44.2%) | | Black or African American | 17 (4.7%) | | White | 185 (51.1%) |
| | Age, n (%) | ≤60 | 177 (47.5%) | | >60 | 196 (52.5%) |
| | Weight, n (%) | ≤70 | 184 (53.2%) | | >70 | 162 (46.8%) |
| | Height, n (%) | <170 | 201 (58.9%) | | ≥170 | 140 (41.1%) |
| | BMI, n (%) | ≤25 | 177 (52.5%) | | >25 | 160 (47.5%) |
| | Residual tumor, n (%) | R0 | 327 (94.8%) | | R1 | 17 (4.9%) | | R2 | 1 (0.3%) |
| | Histologic grade, n (%) | G1 | 55 (14.9%) | | G2 | 178 (48.2%) | | G3 | 124 (33.6%) | | G4 | 12 (3.3%) |
| | Adjacent hepatic tissue inflammation, n (%) | None | 118 (49.8%) | | Mild | 101 (42.6%) | | Severe | 18 (7.6%) |
| | Albumin (g/dl), n (%) | <3.5 | 69 (23%) | | ≥3.5 | 231 (77%) |
| | AFP (ng/ml), n (%) | ≤400 | 215 (76.8%) | | >400 | 65 (23.2%) |
| | Prothrombin time, n (%) | ≤4 | 208 (70%) | | >4 | 89 (30%) |
| | Child-Pugh grade, n (%) | A | 219 (90.9%) | | B | 21 (8.7%) | | C | 1 (0.4%) |
| | Fibrosis Ishak score, n (%) | 0 | 75 (34.9%) | | 1/2 | 31 (14.4%) | | 3/4 | 28 (13%) | | 5/6 | 81 (37.7%) |
| | Vascular invasion, n (%) | No | 208 (65.4%) | | Yes | 110 (34.6%) |
| | Age, median (IQR) | | 61 (52, 69) |
|
|
